

ESMO Breast Cancer Industry Satellite Symposium

# Breaking the Cycle and Building the Next Generation of Treatment for HR+/HER2- MBC

Thursday, 15 May 2025, 17:45–18:45 CEST  
Room 13, Floor 1, ICM – International Congress  
Center Messe München, Munich, Germany

Our expert panel will discuss emerging therapies in HR+/HER2- MBC by building on the current standard of care. Speakers will explore advancements in CDK4i, CDK2i, and KAT6i to inform novel treatment approaches.

## Experts



**Sibylle Loibl, MD, PhD**  
**Chairperson**  
German Breast Group  
Goethe University of Frankfurt  
Frankfurt, Germany



**Mafalda Oliveira, MD, PhD**  
Vall d'Hebron University Hospital  
Barcelona, Spain



**Seth Wander, MD, PhD**  
Harvard Medical School  
Massachusetts General Hospital  
Cambridge, Massachusetts, USA

## Agenda

- |                    |  |
|--------------------|--|
| <b>17:45-17:50</b> | <b>Welcome and Introduction</b><br>Dr. Sibylle Loibl                                       |
| <b>17:50-17:55</b> | <b>Breaking the Cycle—Current Challenges With Frontline Treatment</b><br>Dr. Sibylle Loibl |
| <b>17:55-18:15</b> | <b>From CDK4/6 Inhibition to CDK4-Selective Targeting</b><br>Dr. Seth Wander               |
| <b>18:15-18:20</b> | <b>Mechanisms Driving Treatment Resistance</b><br>Dr. Sibylle Loibl                        |
| <b>18:20-18:40</b> | <b>Beyond the Frontline—Emerging Therapies in HR+/HER2- MBC</b><br>Dr. Mafalda Oliveira    |
| <b>18:40-18:45</b> | <b>Summary</b><br>All speakers   |

CDK2=cyclin-dependent kinase 2; CDK4=cyclin-dependent kinase 4; HER2=human epidermal growth factor receptor 2; HR=hormone receptor; KAT6=lysine acetyltransferase 6; MBC=metastatic breast cancer.

© 2025 Pfizer Inc. All rights reserved. PP-IBR-DEU-4202

